Follow the Unicycive Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Health Care sector, Unicycive Therapeutics, Inc. has recorded 10 reports. Market capitalisation: €140.5m. The latest transaction was disclosed on 1 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Aggarwal Gaurav. Every trade is openly available.
10
Insider Decl.
n/a
Thresholds
€11,855
1 ops.
Buy Volume
n/a
n/a
Sell Volume
40Σ signal
Buys €11,855n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
15,000 shares@ US$0.8250.0054% mcap100.0% of flowCommon StockSEC:0001213900-22-027501:0
Canonical exit: 14 Aug 2022 (T+90)
10 of 10 declarations
Acerca de Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades renales. Cotiza en NASDAQ bajo el símbolo UNCY.